• 1
    Jha, P., R. Kumar, A. Khera, M. Bhattacharya, P. Arora, V. Gajalakshmi. et al. 2010. HIV mortality and infection in India: estimates from nationally representative mortality survey of 1.1 million homes. Br. Med. J. 340:c621.
  • 2
    Girish, K. S., and K. Kemparaju. 2011. Overlooked issues of snakebite management: time for strategic approach. Curr. Top. Med. Chem. 11:24942508.
  • 3
    Mohapatra, B., D. A. Warrell, W. Suraweera, P. Bhatia, N. Dhingra, R. M. Jotkar, et al. 2011. Snakebite mortality in India: a nationally representative mortality survey. PLoS Negl. Trop. Dis. 5:e1018.
  • 4
    Simpson, I. D., and R. L. Norris. 2009. The global snakebite crisis–a public health issue misunderstood, not neglected. Wilderness Environ. Med. 20:4356.
  • 5
    Kasturiratne, A., A. R. Wickremasinghe, N. de Silva, N. K. Gunawardena, A. Pathmeswaran, R. Premaratna, et al. 2008. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 5:e218.
  • 6
    Walker, M. B. 1935. Case showing the Effect of Prostigmin on Myasthenia Gravis. Proc. R. Soc. Med. 28:759761.
  • 7
    Walker, M. B. 1938. Myasthenia Gravis: a Case in which Fatigue of the Forearm Muscles could induce Paralysis of the Extra-ocular Muscles. Proc. R. Soc. Med. 31:722.
  • 8
    Walker, M.. 1946. The treatment of myasthenia gravis. Med. Press 216:8184.
  • 9
    Johnston, J. D. 2007. Mary Broadfoot Walker (1888-1974). J. Neurol. 254:13061307.
  • 10
    Lingle, C. J., and J. H. Steinbach. 1988. Neuromuscular blocking agents. Int. Anesthesiol. Clin. 26:288301.
  • 11
    Buzello, W., and C. Diefenbach. 1992. Curare and its successors. A 50-year's evolution. Anasthesiol Intensivmed Notfallmed Schmerzther 27:290299.
  • 12
    Banerjee, R. N., A. L. Sahni, K. A. Chacko, and K. Vijay. 1972. Neostigmine in the treatment of Elapidae bites. J. Assoc. Physicians India 20:503509.
  • 13
    Watt, G., R. D. Theakston, C. G. Hayes, M. L. Yambao, R. Sangalang, C. P. Ranoa, et al. 1986. Positive response to edrophonium in patients with neurotoxic envenoming by cobras (Naja naja philippinensis). A placebo-controlled study. N. Engl. J. Med. 315:14441448.
  • 14
    Currie, B., M. Fitzmaurice, and J. Oakley. 1988. Resolution of neurotoxicity with anticholinesterase therapy in death-adder envenomation. Med. J. Aust. 148:522525.
  • 15
    WHO. 2010. Guidelines for the management of snake-bites in Southeast Asia. p. 106107.
  • 16
    Warrell, D. A. 2012. Snake bite: a neglected problem in twenty-first century India. Natl Med. J. India 24:321324.
  • 17
    WHO. 2010. Guidelines for the Prevention and Clinical Management of Snakebite in Africa. World Health Organization, Brazzaville, Congo, Pp. 8788.
  • 18
    Fayrer, J. 1884. An Address on the Nature of Snake-Poison; its Effects on Living Creatures, and the Present Aspect of Treatment of the Poisoned. Br. Med. J. 1:205210.
  • 19
    Hawgood, B. J. 1996. Sir Joseph Fayrer MD FRS (1824-1907) Indian Medical Service: snakebite and mortality in British India. Toxicon 34:171182.
  • 20
    Drachman, D. B., D. M. Fambrough, and S. Satyamurti. 1973. Reduced acetylcholine receptors in myasthenia gravis. Trans. Am. Neurol. Assoc. 98:9395.
  • 21
    Fambrough, D. M., D. B. Drachman, and S. Satyamurti. 1973. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182:293295.
  • 22
    Satyamurti, S., D. B. Drachman, and F. Slone. 1975. Blockade of acetylcholine receptors: a model of myasthenia gravis. Science 187:955957.
  • 23
    Drachman, D. B. 1978. Myasthenia gravis (second of two parts). N. Engl. J. Med. 298:186193.
  • 24
    Drachman, D. B. 1978. Myasthenia gravis (first of two parts). N. Engl. J. Med. 298:136142.
  • 25
    Flachsenberger, W., and P. Mirtschin. 1994. Anticholinesterases as antidotes to envenomation of rats by the death adder (Acanthophis antarcticus). Toxicon 32:3539.
  • 26
    Guieu, R., J. P. Rosso, and H. Rochat. 1994. Anticholinesterases and experimental envenomation by Naja. Comp. Biochem. Physiol. C. Pharmacol. Toxicol. Endocrinol. 109:265268.
  • 27
    Dash, S. C., S. K. Ghosh, D. C. Mathur, G. N. Jha, U. Prasad, and K. S. Grewal. 1976. Neurotoxic snake bite–dramatic recovery following neostigmine therapy. J. Assoc. Physicians India 24:535537.
  • 28
    Sharma, S. K., P. Bovier, N. Jha, E. Alirol, L. Loutan, and F. Chappuis. 2013. Effectiveness of Rapid Transport of Victims and Community Health Education on Snake Bite Fatalities in Rural Nepal. Am. J. Trop. Med. Hyg. 00.
  • 29
    Fossati, A., M. G. Vimercati, G. L. Bandi, and A. Formenti. 1990. Pharmacokinetic study of neostigmine after intranasal and intravenous administration in the guinea pig. Drugs Exp. Clin. Res. 16:575579.
  • 30
    Broggini, M., C. Benvenuti, V. Botta, A. Fossati, and M. Valenti. 1991. Bioavailability of intranasal neostigmine: comparison with intravenous route. Methods Find. Exp. Clin. Pharmacol. 13:193198.
  • 31
    Ricciardi, R., B. Rossi, M. Nicora, A. Sghirlanzoni, and A. Muratorio. 1991. Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation. J. Neurol. Neurosurg. Psychiatry 54:10611062.
  • 32
    Dooley, J. M., K. J. Goulden, J. G. Gatien, E. J. Gibson, and B. S. Brown. 1986. Topical therapy for oropharyngeal symptoms of myasthenia gravis. Ann. Neurol. 19:192194.
  • 33
    Sghirlanzoni, A., D. Pareyson, C. Benvenuti, G. Cei, V. Cosi, M. Lombardi, et al. 1992. Efficacy of intranasal administration of neostigmine in myasthenic patients. J. Neurol. 239:165169.
  • 34
    Mebs, D.. 2002. Venomous and Poisonous Animals. CRC Press, Boca Raton, Florida. 339 p.
  • 35
    Sharma, S. K., F. Chappuis, N. Jha, P. A. Bovier, L. Loutan, and S.Koirala. 2004. Impact of snake bites and determinants of fatal outcomes in southeastern Nepal. Am. J. Trop. Med. Hyg. 71:234238.
  • 36
    Alirol, E., S. K. Sharma, H. S. Bawaskar, U. Kuch, and F. Chappuis. 2010. Snake bite in South Asia: a review. PLoS Negl. Trop. Dis. 4:e603.
  • 37
    Sharma, S. K., S. Koirala, G. Dahal, and C. Sah. 2004. Clinico-epidemiological features of snakebite: a study from Eastern Nepal. Trop. Doct. 34:2022.
  • 38
    Warrell, D. A., S. Looareesuwan, N. J. White, R. D. Theakston, M. J. Warrell, W. Kosakarn, et al. 1983. Severe neurotoxic envenoming by the Malayan krait Bungarus candidus (Linnaeus): response to antivenom and anticholinesterase. BMJ 286:678680.
  • 39
    Anil, A., S. Singh, A. Bhalla, N. Sharma, R. Agarwal, and I. D. Simpson. 2010. Role of neostigmine and polyvalent antivenom in Indian common krait (Bungarus caeruleus) bite. J. Infect. Prev. 3:8387.
  • 40
    Chiappinelli, V.. 1996. K-neurotoxins and alpha-neurotoxins: Effect on neuronal nicotinic acetylcholine receptors. pp. 233258 in A. Harvey, ed. Snake Toxins. Pergamon press, New York.
  • 41
    Singh, G., H. S. Pannu, P. S. Chawla, and S. Malhotra. 1999. Neuromuscular transmission failure due to common krait (Bungarus caeruleus) envenomation. Muscle. Nerve. 22:16371643.
  • 42
    Heier, T., J. E. Caldwell, M. L. Sharma, L. D. Gruenke, and R. D. Miller. 1994. Mild intraoperative hypothermia does not change the pharmacodynamics (concentration-effect relationship) of vecuronium in humans. Anesth. Analg. 78:973977.
  • 43
    Heier, T., J. E. Caldwell, J. R. Feiner, L. Liu, T. Ward, and P. M. Wright. 2010. Relationship between normalized adductor pollicis train-of-four ratio and manifestations of residual neuromuscular block: a study using acceleromyography during near steady-state concentrations of mivacurium. Anesthesiology 113:825832.
  • 44
    Heier, T., J. R. Feiner, P. M. Wright, T. Ward, and J. E. Caldwell. 2012. Sex-related differences in the relationship between acceleromyographic adductor pollicis train-of-four ratio and clinical manifestations of residual neuromuscular block: a study in healthy volunteers during near steady-state infusion of mivacurium. Br. J. Anaesth. 108:444451.
  • 45
    Di Costanzo, A., A. Toriello, C. Mannara, C. Benvenuti, and G. Tedeschi. 1993. Intranasal versus intravenous neostigmine in myasthenia gravis: assessment by computer analysis of saccadic eye movements. Clin. Neuropharmacol. 16:511517.
  • 46
    Student's t-Test Calculator.
  • 47
    Brull, S. J., and G. S. Murphy. 2010. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth. Analg. 111:129140.
  • 48
    Curran, R.. 2007. A milestone change in practice: a call for widespread application of intranasal medication delivery in the prehospital environment. Emerg. Med. Serv. 36: 4041, 43-46, 48-49 passim.
  • 49
    Rajpal, S., G. Mittal, R. Sachdeva, M. Chhillar, R. Ali, S. S. Agrawal, et al. 2009. Development of atropine sulphate nasal drops and its pharmacokinetic and safety evaluation in healthy human volunteers. Environ. Toxicol. Pharmacol. 27:206211.
  • 50
    Arora, P., S. Sharma, and S. Garg. 2002. Permeability issues in nasal drug delivery. Drug Discov. Today 7:967975.
  • 51
    Chippaux, J. P. 2008. Estimating the global burden of snakebite can help to improve management. PLoS Med. 5:e221.